While the data is encouraging, a much larger test is underway for Moderna, involving 30,000 humans. The phase 3 trial to determine the safety and efficacy of the vaccine will begin producing data in November or December. The vaccine uses messenger RNA, a synthetic form of the virus’s genetic material designed to push the body’s immune system into attack mode. The US government is providing US $ 955 million to help fund vaccine development.
Moderna stock rose 1.7 percent to US $ 81.24 as of 3:50 p.m. in New York City.